EpiPen Shortage

August 31, 2018

As you may be aware, there have been reports of shortages throughout the country of epinephrine auto-injector products, including brand name EpiPen® and EpiPen Jr.®, and their authorized generics (Epinephrine Injection, USP Auto-injector). Due to the EpiPen shortage, there may also be some shortages throughout the country of two other epinephrine products: brand name AUVI-Q® and the authorized generic for Adrenaclick® (Epinephrine Injection, USP Auto-injector, which is made by Impax Laboratories).

Cigna’s response to the shortage and the customer experience at the pharmacy

We will not be changing the formulary placement (tiering) and utilization management (UM) edits on our epinephrine products. Current coverage is listed below:

<table>
<thead>
<tr>
<th>Product</th>
<th>Value/ Advantage</th>
<th>Standard/ Performance</th>
<th>Legacy</th>
<th>IFP (all formularies)</th>
</tr>
</thead>
<tbody>
<tr>
<td>EpiPen &amp; EpiPen Jr. (brand)</td>
<td>DRT, QL</td>
<td>DRT, QL</td>
<td>Tier 3-NPB, QL</td>
<td>NF, QL</td>
</tr>
<tr>
<td>EpiPen &amp; EpiPen Jr. (AG)</td>
<td>Tier 1-generic, QL</td>
<td>Tier 1-generic, QL</td>
<td>Tier 1-generic, QL</td>
<td>Tier 2, QL</td>
</tr>
<tr>
<td>Adrenaclick (AG)</td>
<td>Tier 1-generic, QL</td>
<td>Tier 1-generic, QL</td>
<td>Tier 1-generic, QL</td>
<td>Tier 2, QL</td>
</tr>
<tr>
<td>AUVI-Q (brand)</td>
<td>DRT, QL</td>
<td>DRT, QL</td>
<td>3-NPB, QL, PA</td>
<td>NF, QL</td>
</tr>
</tbody>
</table>

AG: Authorized generic
DRT/NF: Not covered (unless approved through medical necessity review)
NPB: Non-preferred brand
QL: Quantity limit
PA: Prior authorization

- For formularies where an epinephrine product is not covered, the Cigna Pharmacy Service Center will provide a one-time authorization. Customers who receive coverage for a non-formulary product during the shortage will not incur any additional cost (i.e. Member Pay Difference). They will pay their plan’s non-preferred copay/coinsurance to fill their prescription (if supplies are available).
- Both Mylan and the FDA have provided updates and guidance to the public. To help address the shortage, the FDA has extended the expiration dates on specific lots of brand name EpiPen and its authorized generic by four months. This extension does not apply to brand EpiPen Jr. or its authorized generic.

Thank you for assisting our customers during this shortage.

All Cigna products and services are provided exclusively by or through operating subsidiaries of Cigna Corporation, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Tel-Drug, Inc., Tel-Drug of Pennsylvania, L.L.C., and HMO or service company subsidiaries of Cigna Health Corporation. The Cigna name, logo, and other Cigna marks are owned by Cigna Intellectual Property, Inc.

©2019 Cigna.